d*r
2 楼
RNA一大早跌了80%..
http://www.businessweek.com/news/2013-09-20/prosensa-shares-plu
Bloomberg News
Prosensa Shares Plunge as Muscular Dystrophy Drug Fails in Trial
By Makiko Kitamura September 20, 2013
Prosensa Holding NV (RNA:US) plunged after the Dutch company’s experimental
muscular dystrophy drug failed to help patients walk better in a clinical
trial.
Prosensa sank 71 percent to $7 at 7:55 a.m. New York time in trading (RNA:US
) before U.S. exchanges opened. The company is based in Leiden, the
Netherlands, and listed on the Nasdaq Stock Market. Prosensa is developing
the treatment, drisapersen, with GlaxoSmithKline Plc. (GSK)
Drisapersen failed to help patients more than a placebo in a test of six-
minute walking distance, the companies said in a statement today.
STORY: Former Lehman CFO Erin Callan's Never Going Back
Duchenne muscular dystrophy is a neuromuscular disease with no known cure
that affects one in 3,500 newborn boys.
Glaxo rose 0.1 percent to 1,578 pence in London. Sarepta Therapeutics Inc.
is developing a competing drug.
Prosensa sold shares in June in an initial public offering (RNA:US) at $13
each. The company had a market value of $840.1 million based on yesterday’s
closing share price of $24.
http://www.businessweek.com/news/2013-09-20/prosensa-shares-plu
Bloomberg News
Prosensa Shares Plunge as Muscular Dystrophy Drug Fails in Trial
By Makiko Kitamura September 20, 2013
Prosensa Holding NV (RNA:US) plunged after the Dutch company’s experimental
muscular dystrophy drug failed to help patients walk better in a clinical
trial.
Prosensa sank 71 percent to $7 at 7:55 a.m. New York time in trading (RNA:US
) before U.S. exchanges opened. The company is based in Leiden, the
Netherlands, and listed on the Nasdaq Stock Market. Prosensa is developing
the treatment, drisapersen, with GlaxoSmithKline Plc. (GSK)
Drisapersen failed to help patients more than a placebo in a test of six-
minute walking distance, the companies said in a statement today.
STORY: Former Lehman CFO Erin Callan's Never Going Back
Duchenne muscular dystrophy is a neuromuscular disease with no known cure
that affects one in 3,500 newborn boys.
Glaxo rose 0.1 percent to 1,578 pence in London. Sarepta Therapeutics Inc.
is developing a competing drug.
Prosensa sold shares in June in an initial public offering (RNA:US) at $13
each. The company had a market value of $840.1 million based on yesterday’s
closing share price of $24.
x*n
3 楼
我上上周team member说马上安排onsite,结果上周没消息,这周到现在还没消息。
w*x
6 楼
明天问吧,表现得积极一点。good luck。
f*i
7 楼
打电话问了HR,说还没有安排,又给HM发了邮件骚扰,继续漫长的等待。。。
我人生中最美好的时间都在等待中过去了。。。
我人生中最美好的时间都在等待中过去了。。。
相关阅读
Re: 有没有专门介绍转录引子的网站?第一章 引言C-Bioinformatics, a new yahoo mailing list[转载] for people interested in RNAiRe: Anybody know about immunofluorescence第十四章 视觉觉知Re: protein identification前言第十二章 脑损伤序第六章 知觉瞬间:视觉理论第十五章 一些实验Re: 有人对超声熟悉的吗?Re: RNA extraction关于“自由意志”的跋relative entropy (求教bioinformati 高手Re: 请教关于western blotting的问题Re: Ligation ProblemMouse vs. HumanRe: SOS! 请教如何防止蛋白质在sample buffer 中沉淀